Apyx Medical 향후 성장
Future 기준 점검 1/6
Apyx Medical은 연간 수입과 매출이 각각 4.6%와 15.1% 증가할 것으로 예상되고 EPS는 연간 6.1%만큼 증가할 것으로 예상됩니다.
핵심 정보
4.6%
이익 성장률
6.11%
EPS 성장률
| Medical Equipment 이익 성장 | 16.1% |
| 매출 성장률 | 15.1% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 21 May 2026 |
최근 향후 성장 업데이트
Recent updates
분석 기사 • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Apyx Medical Corporation (NASDAQ:APYX) Price Target To US$6.50
Apyx Medical Corporation ( NASDAQ:APYX ) investors will be delighted, with the company turning in some strong numbers...
내러티브 업데이트 • May 05
APYX: GLP 1 Skin Tightening And New Tools Will Drive Upside
Analysts have raised their Apyx Medical price target to $6 from $5, citing a stronger recent quarter, higher 2026 guidance and added potential from new product approvals, geographic expansion and growing demand linked to GLP-1 usage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent quarter, where sales were in line and earnings were ahead of expectations, as support for a higher valuation framework.내러티브 업데이트 • Apr 21
APYX: GLP-1 Skin Tightening Demand Will Support Future Upside
Analysts have lifted their price targets on Apyx Medical to $6, up from $5, citing a strong quarter; 2026 guidance above prior Street expectations; early traction from the Ayon launch; and potential upside from new product approvals, GLP-1 related skin tightening demand, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $6 price target as reflecting stronger confidence in execution after a quarter where sales were in line and earnings were ahead of prior expectations, which they view as supportive for valuation.내러티브 업데이트 • Apr 05
APYX: GLP-1 Skin Tightening Trend Will Drive Future Upside
Narrative Update on Apyx Medical The updated analyst price target for Apyx Medical moves to $6, with analysts pointing to a strong quarter, 2026 guidance that is ahead of Street expectations, early traction from the Ayon launch, growing skin tightening demand linked to GLP-1 usage, and expansion opportunities outside the U.S. as key supports for the change. Analyst Commentary Recent Street research on Apyx Medical centers on a higher $6 price target and an upgrade to a more constructive stance, driven by operational updates, new product traction, and exposure to GLP-1 related demand trends.내러티브 업데이트 • Mar 22
APYX: GLP-1 Procedure Demand And International Expansion Will Drive Future Upside
Narrative Update: Apyx Medical Apyx Medical's updated fair value estimate edges up from $6.00 to $6.40 as analysts point to a higher Street price target of $6.00, recent earnings outperformance, 2026 guidance that sits above prior expectations, and additional growth opportunities tied to new product approvals, GLP-1 related demand, and international expansion. Analyst Commentary Recent Street commentary on Apyx Medical is broadly constructive, with analysts pointing to a combination of product momentum, new procedure use cases, and international expansion as key inputs to their updated valuation work.내러티브 업데이트 • Mar 06
APYX: Strong Revenue Outlook Will Support Future Single Platform Adoption
Analysts have raised their Apyx Medical price target to $6.00, up from $6.00, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E that together refine their view of the stock's risk and earnings potential. What's in the News Apyx Medical issued preliminary revenue guidance for fourth quarter 2025, with management expecting revenue between $19.0 million and $19.2 million, which the company states represents a 34% year over year increase (Key Developments).내러티브 업데이트 • Feb 19
APYX: Single Console Platform Will Drive Future Adoption And Margin Expansion
Analysts have modestly adjusted their price target framework for Apyx Medical, reflecting updated assumptions around profit margin and future P/E that contribute to a refined view of fair value at $6.00 per share. What's in the News Apyx Medical issued preliminary revenue guidance for the fourth quarter of 2025, with expected revenue between $19.0m and $19.2m, described by the company as approximately 34% year over year growth (company guidance).내러티브 업데이트 • Feb 03
APYX: Single Console Platform Will Drive Wider Adoption And Margin Expansion
Narrative Update on Apyx Medical Analysts have raised their price target on Apyx Medical to US$8, reflecting increased confidence that the AYON all in one console, which integrates Renuvion with additional surgical offerings, can attract physicians through its differentiated technology, workflow benefits, and broad patient appeal. Analyst Commentary Recent research updates are framing Apyx Medical as a company where expectations are increasingly tied to execution on the AYON platform and its potential impact on growth, margins, and valuation.분석 기사 • Feb 03
Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26%
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...내러티브 업데이트 • Jan 20
APYX: Single Console Platform Will Support Future Procedure And Workflow Adoption
Analysts have raised their price target on Apyx Medical to $8, pointing to the AYON system's integrated console design, use of the legacy Renuvion technology, and its appeal to physicians as key supports for the updated view. Analyst Commentary Recent analyst commentary around Apyx Medical has focused on how the AYON system could influence the company’s growth path, execution risks, and valuation framework.분석 기사 • Jan 13
Is Apyx Medical Corporation (NASDAQ:APYX) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$7.24 Apyx Medical is...내러티브 업데이트 • Jan 06
APYX: Single Console Platform Will Drive Future Procedure Adoption Upswing
Analysts have nudged their fair value target for Apyx Medical to $6.00 per share, citing greater confidence in the AYON system's all in one console design and its potential appeal to physicians and a broadening patient base. Analyst Commentary Bullish Takeaways Bullish analysts point to the AYON system's all in one, single console design as a core driver for their higher fair value targets, arguing that a unified platform can support more efficient procedure volumes and revenue per installed unit over time.내러티브 업데이트 • Dec 22
APYX: New Surgical Console Rollout Will Drive Stronger Demand Inflection
Analysts have modestly raised their price target on Apyx Medical to $8.00, citing increasing confidence that the AYON system can drive faster adoption and enhance the company’s long term growth and profitability profile. Analyst Commentary Analyst feedback on Apyx Medical has been largely constructive, with the AYON system viewed as a key catalyst for accelerating revenue growth and improving the company’s valuation profile.내러티브 업데이트 • Dec 08
APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection
Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.내러티브 업데이트 • Nov 24
APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum
Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.분석 기사 • Nov 18
Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...분석 기사 • Nov 07
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Apyx Medical Corporation ( NASDAQ:APYX ), is not the largest company out there, but it received a lot of attention from...내러티브 업데이트 • Nov 07
APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities
Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.분석 기사 • Oct 04
Even With A 26% Surge, Cautious Investors Are Not Rewarding Apyx Medical Corporation's (NASDAQ:APYX) Performance Completely
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...분석 기사 • Sep 19
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jul 26
A Piece Of The Puzzle Missing From Apyx Medical Corporation's (NASDAQ:APYX) 34% Share Price Climb
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...분석 기사 • Apr 23
The Market Doesn't Like What It Sees From Apyx Medical Corporation's (NASDAQ:APYX) Revenues Yet As Shares Tumble 25%
To the annoyance of some shareholders, Apyx Medical Corporation ( NASDAQ:APYX ) shares are down a considerable 25% in...
새로운 내러티브 • Apr 11
AYON Launch And Restructuring Will Create Lasting Opportunities
The launch of the AYON Body Contouring System may significantly drive revenue growth through market expansion and increased equipment sales.분석 기사 • Mar 05
Apyx Medical Corporation's (NASDAQ:APYX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 0.9x Apyx Medical Corporation ( NASDAQ:APYX ) may be sending very bullish...분석 기사 • Dec 19
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
While Apyx Medical Corporation ( NASDAQ:APYX ) might not have the largest market cap around , it led the NASDAQGS...분석 기사 • Nov 23
Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...분석 기사 • Sep 14
Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Key Insights The projected fair value for Apyx Medical is US$1.98 based on 2 Stage Free Cash Flow to Equity Apyx...분석 기사 • Aug 07
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders that were waiting for something to happen have been dealt a blow...분석 기사 • Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Key Insights Apyx Medical will host its Annual General Meeting on 8th of August Salary of US$482.5k is part of CEO...분석 기사 • Jun 19
Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Unfortunately for some shareholders, the Apyx Medical Corporation ( NASDAQ:APYX ) share price has dived 25% in the last...분석 기사 • Mar 26
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Market forces rained on the parade of Apyx Medical Corporation ( NASDAQ:APYX ) shareholders today, when the analysts...분석 기사 • Feb 16
Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
With a price-to-sales (or "P/S") ratio of 1.5x Apyx Medical Corporation ( NASDAQ:APYX ) may be sending bullish signals...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 77 | -5 | -4 | N/A | 2 |
| 12/31/2027 | 66 | -12 | -10 | -10 | 4 |
| 12/31/2026 | 60 | -12 | -10 | -12 | 4 |
| 3/31/2026 | 56 | -9 | -9 | -8 | N/A |
| 12/31/2025 | 53 | -11 | -9 | -8 | N/A |
| 9/30/2025 | 48 | -15 | -9 | -8 | N/A |
| 6/30/2025 | 47 | -17 | -10 | -9 | N/A |
| 3/31/2025 | 47 | -20 | -13 | -12 | N/A |
| 12/31/2024 | 48 | -23 | -19 | -18 | N/A |
| 9/30/2024 | 49 | -28 | -18 | -17 | N/A |
| 6/30/2024 | 49 | -28 | -10 | -9 | N/A |
| 3/31/2024 | 50 | -23 | -10 | -10 | N/A |
| 12/31/2023 | 52 | -19 | -6 | -5 | N/A |
| 9/30/2023 | 50 | -15 | -8 | -8 | N/A |
| 6/30/2023 | 47 | -16 | -17 | -17 | N/A |
| 3/31/2023 | 44 | -21 | -18 | -18 | N/A |
| 12/31/2022 | 45 | -23 | -21 | -20 | N/A |
| 9/30/2022 | 49 | -19 | -17 | -16 | N/A |
| 6/30/2022 | 51 | -18 | -15 | -14 | N/A |
| 3/31/2022 | 52 | -16 | -14 | -13 | N/A |
| 12/31/2021 | 49 | -15 | -11 | -10 | N/A |
| 9/30/2021 | 43 | -15 | -12 | -12 | N/A |
| 6/30/2021 | 38 | -14 | -11 | -11 | N/A |
| 3/31/2021 | 31 | -15 | -11 | -11 | N/A |
| 12/31/2020 | 28 | -12 | -17 | -16 | N/A |
| 9/30/2020 | 25 | -16 | -19 | -18 | N/A |
| 6/30/2020 | 25 | -16 | -21 | -20 | N/A |
| 3/31/2020 | 28 | -16 | -22 | -21 | N/A |
| 12/31/2019 | 28 | -20 | N/A | -18 | N/A |
| 9/30/2019 | 26 | -18 | N/A | -33 | N/A |
| 6/30/2019 | 22 | -15 | N/A | -30 | N/A |
| 3/31/2019 | 19 | -14 | N/A | -25 | N/A |
| 12/31/2018 | 17 | -11 | N/A | -21 | N/A |
| 9/30/2018 | 14 | -10 | N/A | -2 | N/A |
| 6/30/2018 | 13 | -12 | N/A | -1 | N/A |
| 3/31/2018 | 5 | -15 | N/A | -2 | N/A |
| 12/31/2017 | 10 | -14 | N/A | -4 | N/A |
| 9/30/2017 | -12 | -19 | N/A | -5 | N/A |
| 6/30/2017 | -4 | -17 | N/A | -4 | N/A |
| 3/31/2017 | 37 | -4 | N/A | -3 | N/A |
| 12/31/2016 | 9 | -12 | N/A | -3 | N/A |
| 9/30/2016 | 35 | -5 | N/A | -3 | N/A |
| 6/30/2016 | 33 | -5 | N/A | -4 | N/A |
| 3/31/2016 | 31 | -6 | N/A | -6 | N/A |
| 12/31/2015 | 30 | 8 | N/A | -6 | N/A |
| 9/30/2015 | 29 | 4 | N/A | -5 | N/A |
| 6/30/2015 | 28 | 3 | N/A | -3 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: APYX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: APYX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: APYX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: APYX 의 수익(연간 15.1%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: APYX 의 수익(연간 15.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: APYX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 11:11 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Apyx Medical Corporation는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| David Turkaly | Citizens JMP Securities, LLC |